Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma - Wikidata - wikimedia - TriplyDB

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

http://www.wikidata.org/entity/Q34059058

about

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Systematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL)Kaposi's Sarcoma-Associated Herpesvirus Hijacks RNA Polymerase II To Create a Viral Transcriptional Factory.Newly emerging therapies targeting viral-related lymphomas.Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis A role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma.Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.Prognosis in primary effusion lymphoma is associated with the number of body cavities involved.Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis.Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Current status of treatment for primary effusion lymphoma.Primary effusion lymphoma in the absence of HIV infection--clinical presentation and management.Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.Virus reactivation: a panoramic view in human infections Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy.

P2860

Q28481321-4A2538FC-8377-47FC-B183-EAE3153CEB50 Q28544735-7D540923-289C-493D-923B-61C2987CDCAC Q30408885-C3F9BB29-010C-404C-9A0B-32DBFF1E85FA Q30414412-246A3F1C-855B-4A3B-A6B6-EE895A4C3821 Q33690895-AFF286EA-392D-463B-81D9-199F3FF60558 Q33699201-161E0F7F-C21D-437C-920C-CCE1DBEBBA95 Q34245230-FE8CC20D-C0EE-437E-9081-151411DBC619 Q34460823-9B1063F6-D724-4909-82FF-DF8D82F7BC8D Q35046691-D31FE781-4904-47E6-862D-58E91F28109F Q35124404-A674B905-D8F0-45B8-9BE6-64C3D30657F7 Q35832168-7F01D78E-D121-4F50-AAB8-0833179E8239 Q36890993-E32158A6-5518-4F84-915C-00556824C77A Q36968066-697E21A0-917F-465C-A649-3D1A19151B1D Q37098844-00D330A3-7A8E-407A-A764-A53911221604 Q37417526-E17256E3-0F79-4BE5-BB27-CDB8F50D4FC2 Q37683385-4951FC15-84DC-4D8D-BE15-75570B1D52FF Q37810431-FEFE151A-C6E6-4021-B285-181D2DE349EF Q37910910-45158DD1-EB75-43B5-BAE1-B821DDA8DE7F Q38010467-B96BDEDF-549C-4117-8C0D-0CF9A9622590 Q38160783-0C181E91-F4E9-4DD6-8662-D9D036EAF513 Q38194434-654C1C0F-8880-42C1-A3B8-9CF1C1D382FB Q38227506-38FDFB56-2791-47C2-B4F2-5BFDF4100F5B Q38264454-F8D0121D-0799-4269-8409-C831A7B2F96E Q38270091-5EBE1460-8955-4F20-9AB8-2E16E6796A78 Q38449592-DA9E1288-1773-413C-B760-8CF0094ACB50 Q38605346-A56245FD-9712-406B-AB54-570DD7DF487E Q38943741-61EE3712-EF8A-4C30-9493-5B98AAEE5420 Q39103566-D589D8B6-2B16-4F56-8AF0-232DC6B14DC6 Q39723484-E750F8A0-8DA8-49ED-8CA3-D3D297F8FD48 Q45324502-BAC6E3FE-FAFA-426A-9E41-35C337DE1C5F Q48330061-D8C65014-BF70-496E-9C0A-B2BC41375C63

P2860

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

http://www.wikidata.org/entity/Q34059058

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@ast

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@en

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@nl

type

label

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@ast

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@en

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@nl

prefLabel

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@ast

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@en

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@nl

P1433

Q34059058-7B9248DF-3384-47FA-AE65-B9FD396012C3

P1476

Q34059058-0FF03D1B-A524-4ECE-B229-AAB18A98D5B9

P2093

Q34059058-05E1555D-7F1B-47A2-9111-212253E2FA6A

Q34059058-2B801458-6BF2-4EB8-914C-C836B1287131

Q34059058-4B0F225C-5D12-48BB-B779-6BF7A4BFB62D

Q34059058-6E34FAB9-6BE0-4F51-84EA-3519979C50D1

Q34059058-85C2C545-886E-43FD-8450-E730F75B6C02

Q34059058-A65CCCD2-4D36-46E5-945A-B114AFDBDC2A

Q34059058-A8266FA5-C788-4A6D-8750-78FC5E4F7071

Q34059058-D5840FE7-80E8-40D3-BBC0-A7C7531718D3

Q34059058-EC80B637-8A39-4BD8-947B-8F5D2653023A

P2860

Q34059058-052850B1-4DB7-4FA5-8F5C-C65706AE5117

Q34059058-07387235-1482-42AF-9C45-820EDBE4981C

Q34059058-0B975C62-1095-4349-90B8-BE485D1BF280

Q34059058-1283ADA8-B01A-4606-8A32-8549361F9E46

Q34059058-1362A569-49FD-40AE-9EE0-A35DB0EF3D0C

Q34059058-1EE3D940-BF40-41B9-B17E-23F47041F996

Q34059058-1F18439F-2EE6-477C-9F4B-4F7A8EEFAB72

Q34059058-274CD9F4-54D7-4DF9-9F9C-129A08819540

Q34059058-28538FFC-5E4B-4BFF-AA00-FB640C90F5D2

Q34059058-2B746FC0-A3C9-403F-9A8E-3C324F3AB5ED

P304

Q34059058-23FF8BCE-9447-43BD-A4BB-ECC904B253E6

P31

Q34059058-BA0C4DF1-5334-4725-94AC-D305D9E9B0AC

P356

Q34059058-C0992AD7-40CA-47EF-8A07-C9D2C3A572D4

P407

Q34059058-36DE5756-0187-4574-BDDA-D692AEF9C48F

P433

Q34059058-24C9C56C-74B2-4AA5-A9DF-9EEF0B223E99

P478

Q34059058-7B6CD577-C306-425D-8B9C-E02F9AA8CFAA

P50

Q34059058-35CAC861-C0C6-43C8-8117-A6FBD8061E57

P577

Q34059058-64BB21E7-3216-4353-84D0-B39DF41A819F

P5875

Q34059058-D5094DFD-5640-48E3-A8AF-558A81850687

P698

Q34059058-FFD43B90-63C3-476F-B457-3F36E180054F

P921

Q34059058-5156102C-3BAF-4F13-9C1D-8A0FEE285F7F

P932

Q34059058-63B603C2-B879-4A22-9019-7562DC1DB593

P356

PNAS.1002985107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

@en

P2093

Andrew J Gentles

http://www.w3.org/2001/XMLSchema#string

Enrique A Mesri

http://www.w3.org/2001/XMLSchema#string

Izidore S Lossos

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Ramos

http://www.w3.org/2001/XMLSchema#string

Lucas E Cavallin

http://www.w3.org/2001/XMLSchema#string

Ngoc L Toomey

http://www.w3.org/2001/XMLSchema#string

Shruti Bhatt

http://www.w3.org/2001/XMLSchema#string

Wilfredo Blasini

http://www.w3.org/2001/XMLSchema#string

Yasodha Natkunam

http://www.w3.org/2001/XMLSchema#string

P2860

The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling.

Global mapping of c-Myc binding sites and target gene networks in human B cells

Myc pathways provoking cell suicide and cancer

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

The tumor microenvironment controls primary effusion lymphoma growth in vivo

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

Primary effusion lymphoma

Regulated translation initiation controls stress-induced gene expression in mammalian cells

The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

P304

13069-13074

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1002985107

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Kristopher A Sarosiek

P577

2010-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45113523

http://www.w3.org/2001/XMLSchema#string

P698

20615981

http://www.w3.org/2001/XMLSchema#string

P921

P932

2919898

http://www.w3.org/2001/XMLSchema#string